Literature DB >> 8608623

Neointimal thickening after severe coronary artery injury is limited by a short-term administration of a factor Xa inhibitor. Results in a porcine model.

R S Schwartz1, D J Holder, D R Holmes, J P Veinot, A R Camrud, M A Jorgenson, R G Johnson.   

Abstract

BACKGROUND: Fibrin- and platelet-rich thrombus formations occur as the initial event after percutaneous transluminal coronary angioplasty. We therefore tested the hypothesis that short-term administration of the recombinant tick anticoagulant peptide (rTAP), a factor Xa inhibitor, would reduce the thickness of neointima at 28 days after injury in a porcine coronary balloon angioplasty model. METHODS AND
RESULTS: Continuous intravenous infusion of rTAP (average dose, 194 micrograms . kg-1 . min-1) or placebo (vehicle only) was given to the study pigs for 60 hours. The goal of anticoagulation was to maintain the activated clotting time at 200 seconds. A central venous catheter was inserted 2 days before the procedure. On the day of coronary injury, the animals were administered boluses of rTAP (6.5 mg) and then underwent injury with an oversized metallic coil by standard methods in the right, circumflex, or left anterior descending coronary artery. No significant difference in vascular injury between rTAP and vehicle control was observed after euthanasia at 28 days. Significantly less neointimal thickening occurred in the rTAP-treated animals (thickness, mean +/-SD: 0.30 +/-0.08 mm) compared with the control (0.48 +/- 0.12 mm, P< .001).
CONCLUSIONS: The specific factor Xa inhibitor rTAP, when given in fully anticoagulant doses for a short duration after coronary artery injury in the porcine model, resulted in a long-term decrease in neointimal thickness. These results implicate thrombin generation in neointimal formation and suggest that administration of a potent antithrombotic for several days immediately after the procedure may influence the long-term outcome of the coronary injury with a decrease in neointimal formation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608623     DOI: 10.1161/01.cir.93.8.1542

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Role of clot-associated (-derived) thrombin in cell proliferation induced by fibrin clots in vitro.

Authors:  E Gandossi; C Lunven; C N Berry
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

2.  Factor Xa-A pleuripotential protease.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2003-02       Impact factor: 2.300

3.  A synthetic selective inhibitor of factor Xa, DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver.

Authors:  Y Yamaguchi; K Okabe; J Liang; F Matsumura; H Ohshiro; K Ishihara; T Matsuda; M Takeya; J I Kuratsu; K Mori; S Yamada; M Ogawa
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

4.  A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice.

Authors:  Yoshiyuki Morishima; Yuko Honda
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

5.  Bolus injections of novel thrombogenic site-targeted fusion proteins comprising annexin-V and Kunitz protease inhibitors attenuate intimal hyperplasia after balloon angioplasty.

Authors:  Yung-Hsin Yeh; Shang-Hung Chang; Shin-Yu Chen; Chih-Jen Wen; Fu-Chan Wei; Rui Tang; Sam Achilefu; Tze-Chein Wun; Wei-Jan Chen
Journal:  Int J Cardiol       Date:  2017-04-06       Impact factor: 4.164

6.  Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis.

Authors:  D L Tharp; B R Wamhoff; H Wulff; G Raman; A Cheong; D K Bowles
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-02-28       Impact factor: 8.311

Review 7.  The representative porcine model for human cardiovascular disease.

Authors:  Yoriyasu Suzuki; Alan C Yeung; Fumiaki Ikeno
Journal:  J Biomed Biotechnol       Date:  2010-12-28

8.  Assessment of Novel Anti-thrombotic Fusion Proteins for Inhibition of Stenosis in a Porcine Model of Arteriovenous Graft.

Authors:  Christi M Terry; Ilya Zhuplatov; Yuxia He; Tze-Chein Wun; Seong-Eun Kim; Alfred K Cheung
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

9.  Coronary Injury Score Correlates with Proliferating Cells and Alpha-Smooth Muscle Actin Expression in Stented Porcine Coronary Arteries.

Authors:  Vicki J Swier; Lin Tang; Kristopher D Krueger; Mohamed M Radwan; Michael G Del Core; Devendra K Agrawal
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.